We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
IgG4-RD Case Conversations: Diagnosing Pancreaticobiliary Manifestations and Ruling Out Malignancy
Yasmin Genevieve Hernandez-Barco, MD
Avinash Kambadakone-Ramesh, MD, DNB, FRCR
IgG4-RD Case Conversations: Systemic Disease Infiltrating the Skull Base
John H. Stone, MD, MPH
Bart K. Chwalisz, MD
Marcela Marsiglia, MD, PhD
IgG4-RD Case Conversations: The Peculiarities of Kidney Involvement
Giacomo Quattrocchio, MD
Lynn D. Cornell, MD
Consensus Recommendations for Use of p16/Ki-67 Dual Staining Cytology in the Management of Individuals Testing Positive for HPV
Warner K. Huh, MD
Kimberly Levinson, MD, MPH
Unlocking the Potential of HER3-Targeted Therapy: Breakthroughs in EGFR-Mutant NSCLC Therapeutic Approaches
Jyoti Patel, MD
Pasi Antero Jänne, MD, PhD
Unlocking the Potential of HER2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Helena Yu, MD
Unlocking the Potential of TROP2-Targeted Therapy: Breakthroughs in NSCLC Therapeutic Approaches
Benjamin Levy, MD
Alexander Spira, MD, PhD, FACP
First-Line Targeted Therapies for ROS1 Fusion-Positive Lung Cancers
Alexander Drilon, MD
Overcoming Acquired TKI-Resistance with Next-generation ROS1-TKI Agents
Charu Aggarwal, MD, MPH
The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC
Next-Generation TKI Therapy for ROS1-Rearranged NSCLC
Safety and Tolerability of ROS1 Tyrosine Kinase Inhibitors
Intracranial Activity of ROS1 TKIs
Case: Treatment Selection for ROS1-Rearranged NSCLC Patient with Brain Metastases
Treatment Strategy of ROS1-Rearranged NSCLC in TKI-Naive Patient
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education